Evercore ISI Assumes Astria Therapeutics (ATXS) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/9/2026
- Wall St headed for weekly gains as earnings season nears
- Oil falls as Trump comments on Iran talks ease supply concerns
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- UBS flags level in gold prices where dip buyers will likely emerge
- Telecom stocks tumble on SpaceX spectrum acquisition news
Tweet
Share
E-mailGet Alerts ATXS Hot Sheet
Price: $12.58 --0%
Rating Summary:
2 Buy, 6 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 14 | New: 37
Rating Summary:
2 Buy, 6 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 14 | New: 37
Join SI Premium – FREE
Evercore ISI analyst Gavin Clark-Gartner assumes coverage on Astria Therapeutics (NASDAQ: ATXS) with a Outperform rating and a price target of $25.00.
For an analyst ratings summary and ratings history on Astria Therapeutics click here. For more ratings news on Astria Therapeutics click here.
Shares of Astria Therapeutics closed at $6.79 yesterday.
You May Also Be Interested In
- Raymond James Starts Quince Therapeutics Inc. (QNCX) at Outperform
- Citi initiates Fortune Brands coverage with Buy rating, $48 target
- JPMorgan Resumes Trane Technologies (TT) at Overweight
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
